Firebrick Pharma Ltd: Change of Director's Interest Notice - Peter Molloy
Firebrick Pharma Ltd: Nasodine Phase 1 Paper Published
Firebrick Pharma Ltd: Firebrick Launches Nasodine in Singapore
Firebrick Pharma Ltd: Change in substantial holding
Firebrick Pharma Ltd: Notification regarding unquoted securities - FRE
Firebrick Pharma Ltd: Change in substantial holding - Stephen Goodall
Firebrick Pharma Ltd: Change in substantial holding - Peter Molloy
Firebrick Pharma Ltd: Cleansing Notice
Firebrick Pharma Ltd: Application for quotation of securities - FRE
Firebrick Pharma Ltd: Nasodine Composition Patent Granted in South Africa
Firebrick Pharma Ltd: Proposed issue of securities - FRE
Firebrick Pharma Ltd: Firebrick Raises $800,000 via Placement
Firebrick Pharma Ltd: Notice of Change in Auditor
Firebrick Pharma Ltd: Cleansing Notice
Firebrick Pharma Ltd: Application for quotation of securities - FRE
Firebrick Pharma Ltd: March 2024 Quarterly Activity Report & Appendix 4C
Firebrick Pharma Ltd: Nasodine Nasal Spray Launch in the USA
Firebrick Pharma Ltd: Nasodine Phase 2 COVID-19 Trial Results Published
Firebrick Pharma Ltd: Becoming a substantial holder
Firebrick Pharma Ltd: Nasodine COVID-19 Patent Allowed in US
No Data